Welcome to our dedicated page for Tempus AI SEC filings (Ticker: TEM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tempus AI, Inc. (NASDAQ: TEM) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Tempus is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, and its filings offer insight into how it reports financial performance, manages capital, and documents material corporate events.
Investors can review Form 8-K filings where Tempus discloses items such as preliminary financial results, earnings press releases, credit agreement amendments, securities offerings, and other significant developments. For example, Tempus has used 8-K reports to furnish quarterly financial information, describe an automatic shelf registration statement and related prospectus supplement, and detail the terms of its convertible senior notes due 2030, including conversion features, redemption provisions, and associated capped call transactions.
Over time, this page will also surface Tempus’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically include segment information for its Diagnostics and Data and applications businesses, risk factor discussions, and management’s analysis of operations. In addition, users can expect access to ownership and insider transaction disclosures, such as Form 4 filings, when they are available from EDGAR.
Stock Titan enhances these documents with AI-powered summaries that explain key points from lengthy filings in clear language. Real-time updates from EDGAR help ensure that new TEM filings appear promptly, while AI-generated highlights can draw attention to important terms in credit agreements, securities offerings, or covenant changes. This combination allows readers to navigate Tempus’s regulatory history more efficiently, from capital structure details to ongoing financial reporting.
Tempus AI, Inc. Chief Financial Officer James William Rogers reported two transactions in Class A common stock. He received a grant or award of 37,496 shares at no cost, consisting of fully vested restricted stock units and earned performance-based stock units tied to previously established goals.
Rogers also sold 10,084 shares at a weighted average price of $59.05 per share to cover statutory tax withholding obligations arising from the vesting of restricted stock units. This was a mandatory "sell to cover" transaction under the company’s equity incentive plans, not a discretionary sale.
Erik Phelps reported proposed sales of Common stock in a Form 144 notice. The filing lists the sale of 3,823 shares tied to Restricted Stock Units with a transaction date of
TEM insider filed Form 144 reporting an intended sale of
The filing lists prior 10b5-1 sales of
TEM submitted a Form 144 notifying a proposed sale of Class A Common Stock through Morgan Stanley Smith Barney LLC. The filing lists Restricted Stock Units granted on
Andrew Polovin reported sales of Class A Common Stock under 10b5‑1 transactions. The filing lists two sales in November 2025: 6,387 shares on
Morgan Stanley Smith Barney LLC filed a Form 144 reporting sales of Class A Common Stock for related holders. The filing lists multiple sell transactions between
TEM submitted a Form 144 notice for proposed sales of Class A Common Stock through broker Morgan Stanley Smith Barney LLC. The filing lists restricted stock units granted on
TEM submitted a Form 144 notice reporting a proposed sale of 1,302 shares of Class A Common Stock under a 10b5-1 plan on
The filing lists scheduled restricted stock units: 336 vested on
TEM Form 144 notice shows a reported sale of 19,966 shares of Class A Common Stock by James William Rogers on
The filing also lists several restricted stock unit grants by the issuer with grant dates ranging from
TEM filed a Form 144 to sell 3,814 shares of Common Stock. The filing lists these shares as related to Restricted Stock Units granted on